Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | KIF11 | P52732 | 1/20 | 0.52 |
| ▸ | RAPGEF4 | Q8WZA2 | 2/20 | 0.50 |
| ▸ | XPO1 | O14980 | 2/20 | 0.47 |
| ▸ | IDH2 | P48735 | 1/20 | 0.44 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 2/20 | 0.41 |
| ▸ | P2RX1 | P51575 | 5/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CES2 | O00748 | 1/20 | 0.41 |
| ▸ | ACP1 | P24666 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | TMPRSS4 | Q9NRS4 | 1/20 | 0.39 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.38 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1968509 | 0.97 | MAPT (0.53) | MAPTKIF11RAPGEF4XPO1IDH2 | |
| SCHEMBL25811174 | 0.91 | MAPT (0.48) | MAPTKIF11RAPGEF4XPO1IDH2 | |
| SCHEMBL13181873 | 0.88 | RAPGEF4 (0.55) | MAPTKIF11RAPGEF4XPO1IDH2 | |
| SCHEMBL7944387 | 0.86 | KIF11 (0.45) | MAPTKIF11RAPGEF4XPO1IDH2 | |
| SCHEMBL13450015 | 0.84 | KIF11 (0.44) | MAPTKIF11RAPGEF4XPO1IDH2 | |
| SCHEMBL22421803 | 0.84 | KIF11 (0.44) | MAPTKIF11RAPGEF4XPO1IDH2 | |
| SCHEMBL12706897 | 0.84 | RAPGEF4 (0.57) | MAPTKIF11RAPGEF4XPO1IDH2 | |
| SCHEMBL13169800 | 0.84 | ACP1 (0.47) | MAPTKIF11RAPGEF4XPO1IDH2 | |
| SCHEMBL13223483 | 0.84 | MAPT (0.47) | MAPTKIF11RAPGEF4XPO1IDH2 | |
| SCHEMBL20040714 | 0.84 | KIF11 (0.44) | MAPTKIF11RAPGEF4XPO1IDH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260042743-A1 | SUBSTITUTED BENZIMIDAZOLES FOR TREATING VIRAL DISEASES | COUNCIL SCIENT IND RES (IN) | 2026-02-12 | — | — | US | disclosed |
| EP-4565566-A1 | SUBSTITUTED BENZIMIDAZOLES FOR TREATING VIRAL DISEASES | Council of Scientific and Industrial Research, an Indian Registered Body Incorporated under Regn. of Soc. Act (Act XXI of 1860) (IN) | 2025-06-11 | — | — | EP | disclosed |
| US-20240239749-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X2 AND RELATED PRODUCTS AND METHODS | ESCIENT PHARMACEUTICALS INC (US) | 2024-07-18 | — | — | US | disclosed |
| WO-2024028893-A1 | SUBSTITUTED BENZIMIDAZOLES FOR TREATING VIRAL DISEASES | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH AN INDIAN REGISTERED BODY INCORPORATED UNDER THE REGN. OF SOC. ACT (ACT XXI OF 1860) (IN) | 2024-02-08 | — | — | WO | disclosed |
| EP-4182303-B1 | THERMODYNAMICALLY STABLE FORM OF SCO-101 | SCANDION ONCOLOGY AS (DK) | 2023-11-29 | — | — | EP | disclosed |
| US-RE49686-E1 | Nitrogen-containing heterocyclic compound and use of same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-10-10 | — | — | US | disclosed |
| US-RE49686-E1 | Nitrogen-containing heterocyclic compound and use of same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-10-10 | — | — | US | disclosed |
| CN-114941145-B | Synthesis method of aziridine derivatives | 天津理工大学 | 2023-08-18 | — | — | CN | disclosed |
| CN-114805093-B | Preparation method of diarylamines | 暨南大学 | 2023-04-25 | — | — | CN | disclosed |
| EP-4106030-A1 | SHEET RESISTANCE COMPONENT | Novaled GmbH (DE) | 2022-12-21 | — | — | EP | disclosed |
| US-20070185059-A1 | Antiallergic agents | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2007-08-09 | — | — | US | disclosed |
| US-20070185110-A1 | Antiallergic agents | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2007-08-09 | — | — | US | disclosed |
| EP-1678185-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-07-12 | — | — | EP | disclosed |
| US-20060122243-A1 | Antiallergic | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2006-06-08 | — | — | US | disclosed |
| US-20060100257-A1 | Inhibitors against the activation of ap-1 and nfat | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2006-05-11 | — | — | US | disclosed |
| WO-2005042542-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO (2,1-B) OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-05-12 | — | — | WO | disclosed |
| WO-2004058234-A2 | PHARMACEUTICAL COMBINATIONS OF PHTHALAZINE VEGF INHIBITORS AND BENZAMIDE HDAC INHIBITORS | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-07-15 | — | — | WO | disclosed |
| EP-1237849-A1 | ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE | UNIVERSITY COLLEGE LONDON (GB) | 2002-09-11 | — | — | EP | disclosed |
| WO-2001032604-A1 | ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE | UNIVERSITY COLLEGE LONDON (GB) | 2001-05-10 | — | — | WO | disclosed |
| EP-0118093-A1 | Trichloroacryloyl urea derivatives, process for their preparation and their use as fungicides in agriculture and horticulture | NIHON TOKUSHU NOYAKU SEIZO K.K. (JP) | 1984-09-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122243-A1 | Antiallergic | EPX, NAT1, HNMT | MAPT 2797/4885KIF11 4116/4885RAPGEF4 4609/4885 |
| US-20060100257-A1 | Inhibitors against the activation of ap-1 and nfat | NFATC1, AP1G1, ATF1 | MAPT 3490/4885KIF11 4830/4885RAPGEF4 1091/4885 |
| US-20240239749-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X2 AND RELATED PRODUCTS AND METHODS | MRGPRX2, MRGPRX1, MRGPRX4 | MAPT 4569/4885KIF11 1494/4885RAPGEF4 449/4885 |
| US-20070185110-A1 | Antiallergic agents | NAT1, EPX, AHR | MAPT 2469/4885KIF11 4190/4885RAPGEF4 4541/4885 |
| US-20070185059-A1 | Antiallergic agents | NAT1, EPX, AHR | MAPT 2415/4885KIF11 4154/4885RAPGEF4 4479/4885 |
| US-20260042743-A1 | SUBSTITUTED BENZIMIDAZOLES FOR TREATING VIRAL DISEASES | ACE2, SARS1, NR3C2 | MAPT 4297/4885KIF11 2408/4885RAPGEF4 4710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.